Witter F, Barouki F, Griffin D, Nadler P, Woods A, Wood D, Lietman P
Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Clin Pharmacol Ther. 1987 Nov;42(5):567-75. doi: 10.1038/clpt.1987.198.
The kinetics of the antiviral effect of intramuscular and intravenous injections of recombinant human interferon alpha 2a were investigated in healthy volunteers. Cohorts of eight to 11 subjects received single intramuscular injections of either 0.3 X 10(6), 3 X 10(6), or 18 X 10(6) U or an intravenous infusion of 18 X 10(6) U over 30 minutes. Serial samples of peripheral blood mononuclear cells were analyzed for antiviral effects including both (2'-5') oligoadenylate synthetase activity and resistance to vesicular stomatitis virus infection in vitro. A dose-response relationship was established between recombinant human interferon alpha 2a dose and both vesicular stomatitis virus resistance and (2'-5') oligoadenylate synthetase activity. At the 0.3 X 10(6) U dose an antiviral effect occurred without clinical side effects. The presence of clinical side effects is not necessary for an antiviral effect.
在健康志愿者中研究了肌肉注射和静脉注射重组人干扰素α2a的抗病毒作用动力学。8至11名受试者组成的队列接受了单次肌肉注射，剂量分别为0.3×10⁶、3×10⁶或18×10⁶单位，或在30分钟内静脉输注18×10⁶单位。对外周血单个核细胞的系列样本进行分析，以检测抗病毒效果，包括（2'-5'）寡腺苷酸合成酶活性和体外对水疱性口炎病毒感染的抵抗力。在重组人干扰素α2a剂量与水疱性口炎病毒抵抗力和（2'-5'）寡腺苷酸合成酶活性之间建立了剂量反应关系。在0.3×10⁶单位剂量时出现了抗病毒作用，且无临床副作用。抗病毒作用并不一定需要有临床副作用。
